GeneThera Inc. and Hudson Robotics Inc. announced that they have entered into a worldwide exclusive collaboration agreement to develop the next generation of Integrated Automated Robotic Systems (IARS) molecular diagnostic platform for animal testing of Tuberculosis and Paratuberculosis. As part of the exclusive collaboration agreement, Hudson Robotics will receive a 10% equity ownership of GeneThera stock. Hudson Robotics' and GeneThera's molecular diagnostic and robotic platform is the most advanced system designed to date for animal diagnostics.

This platform has the potential of changing the way animal testing will be done in the future.